Programme
Programme
Day 1 : Scientific basis and clinical studies
Day 1 : Scientific basis and clinical studies
The first day focuses on the scientific foundations and clinical research of psychedelic-assisted therapies. It explores the mechanisms of action of different psychedelic compounds, findings from clinical studies, and the implementation of psychedelic-assisted therapies in clinical practice.
Simultaneous interpretation into English will be provided for all presentations delivered in Estonian.
09:30–09:35
·
Opening remarks
09:35–09:50
Why Do We Need New Treatments in Mental Health Care? The Estonian Situation
Doing nothing also has consequences. When existing treatments leave many people behind, exploring safe and evidence-based innovations becomes both a scientific and a moral responsibility.
Anne Kleinberg, MD
Child and adolescent psychiatrist, psychotherapist (Kleinberg); Vice Chairman of the Board (Estonian Psychiatric Society)
09:35–09:50
Why Do We Need New Treatments in Mental Health Care? The Estonian Situation
Doing nothing also has consequences. When existing treatments leave many people behind, exploring safe and evidence-based innovations becomes both a scientific and a moral responsibility.
Anne Kleinberg, MD
Child and adolescent psychiatrist, psychotherapist (Kleinberg); Vice Chairman of the Board (Estonian Psychiatric Society)
09:35–09:50
Why Do We Need New Treatments in Mental Health Care? The Estonian Situation
Doing nothing also has consequences. When existing treatments leave many people behind, exploring safe and evidence-based innovations becomes both a scientific and a moral responsibility.
Anne Kleinberg, MD
Child and adolescent psychiatrist, psychotherapist (Kleinberg); Vice Chairman of the Board (Estonian Psychiatric Society)
09:50–10:35
Keynote
Psychedelics and Psychiatry – Facts, Hope and Fears
This presentation explores how psychedelics such as psilocybin, LSD and DMT affect the brain and what brain imaging studies reveal about their potential in treating depression, addiction, anorexia and OCD. It also examines the implications of these findings for the future of psychedelic medicine.
Prof. Dr. med. David Nutt
Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit (Imperial College London)
09:50–10:35
Keynote
Psychedelics and Psychiatry – Facts, Hope and Fears
This presentation explores how psychedelics such as psilocybin, LSD and DMT affect the brain and what brain imaging studies reveal about their potential in treating depression, addiction, anorexia and OCD. It also examines the implications of these findings for the future of psychedelic medicine.
Prof. Dr. med. David Nutt
Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit (Imperial College London)
09:50–10:35
Peaesineja
Psychedelics and Psychiatry – Facts, Hope and Fears
This presentation explores how psychedelics such as psilocybin, LSD and DMT affect the brain and what brain imaging studies reveal about their potential in treating depression, addiction, anorexia and OCD. It also examines the implications of these findings for the future of psychedelic medicine.
Prof. Dr. med. David Nutt
Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit (Imperial College London)
10:35–11:20
MDMA-Assisted Therapy for PTSD: Clinical Evidence, Therapeutic Mechanisms, and the Emerging Psychedelic Horizon
This talk explores the current evidence for MDMA-assisted therapy in the treatment of post-traumatic stress disorder (PTSD), including findings from Phase 2 and 3 clinical trials involving treatment-resistant populations. It examines the neurobiological mechanisms that may support trauma-focused psychotherapy and contribute to therapeutic outcomes. Drawing on experience from the Cambridge Psychedelic Research Group, the talk also considers the potential of other psychedelic compounds, including psilocybin, for the treatment of trauma-related conditions.
Liliana Galindo, MD, PhD
Consultant Psychiatrist and Medical Leader in Psychosis (Cambridgeshire and Peterborough NHS Foundation Trust); Affiliated Assistant Professor of Psychiatry (University of Cambridge)
10:35–11:20
MDMA-Assisted Therapy for PTSD: Clinical Evidence, Therapeutic Mechanisms, and the Emerging Psychedelic Horizon
This talk explores the current evidence for MDMA-assisted therapy in the treatment of post-traumatic stress disorder (PTSD), including findings from Phase 2 and 3 clinical trials involving treatment-resistant populations. It examines the neurobiological mechanisms that may support trauma-focused psychotherapy and contribute to therapeutic outcomes. Drawing on experience from the Cambridge Psychedelic Research Group, the talk also considers the potential of other psychedelic compounds, including psilocybin, for the treatment of trauma-related conditions.
Liliana Galindo, MD, PhD
Consultant Psychiatrist and Medical Leader in Psychosis (Cambridgeshire and Peterborough NHS Foundation Trust); Affiliated Assistant Professor of Psychiatry (University of Cambridge)
10:35–11:20
MDMA-Assisted Therapy for PTSD: Clinical Evidence, Therapeutic Mechanisms, and the Emerging Psychedelic Horizon
This talk explores the current evidence for MDMA-assisted therapy in the treatment of post-traumatic stress disorder (PTSD), including findings from Phase 2 and 3 clinical trials involving treatment-resistant populations. It examines the neurobiological mechanisms that may support trauma-focused psychotherapy and contribute to therapeutic outcomes. Drawing on experience from the Cambridge Psychedelic Research Group, the talk also considers the potential of other psychedelic compounds, including psilocybin, for the treatment of trauma-related conditions.
Liliana Galindo, MD, PhD
Consultant Psychiatrist and Medical Leader in Psychosis (Cambridgeshire and Peterborough NHS Foundation Trust); Affiliated Assistant Professor of Psychiatry (University of Cambridge)
11:20–11:50
·
Coffee break
11:50-12:35
From Trip‑Sitting to Extensive Psychotherapy: the Meaning of Therapy in Psychedelic Interventions
Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
11:50-12:35
From Trip‑Sitting to Extensive Psychotherapy: the Meaning of Therapy in Psychedelic Interventions
Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
11:50-12:35
From Trip‑Sitting to Extensive Psychotherapy: the Meaning of Therapy in Psychedelic Interventions
Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
12:35–13:20
Psychedelic treatments in Psychiatry: Promises, Challenges and European Collaborations To Address Them
The session explores the potential of psychedelic-assisted therapy for patients who do not respond to current mental health treatments. It highlights two major European research projects, PsyPal and INTEGRATE, and examines the challenges that must be addressed to ensure the safe and effective implementation of psychedelic treatments.
prof. dr. R.A. Robert Schoevers
Professor of Psychiatry and Head of Department Psychiatry (University Medical Center Groningen)
12:35–13:20
Psychedelic treatments in Psychiatry: Promises, Challenges and European Collaborations To Address Them
The session explores the potential of psychedelic-assisted therapy for patients who do not respond to current mental health treatments. It highlights two major European research projects, PsyPal and INTEGRATE, and examines the challenges that must be addressed to ensure the safe and effective implementation of psychedelic treatments.
prof. dr. R.A. Robert Schoevers
Professor of Psychiatry and Head of Department Psychiatry (University Medical Center Groningen)
12:35–13:20
Psychedelic treatments in Psychiatry: Promises, Challenges and European Collaborations To Address Them
The session explores the potential of psychedelic-assisted therapy for patients who do not respond to current mental health treatments. It highlights two major European research projects, PsyPal and INTEGRATE, and examines the challenges that must be addressed to ensure the safe and effective implementation of psychedelic treatments.
prof. dr. R.A. Robert Schoevers
Professor of Psychiatry and Head of Department Psychiatry (University Medical Center Groningen)
13:20–14:20
·
Llunch break
14:20-15:05
Conversation between psychiatrist and patient
Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
14:20-15:05
Conversation between psychiatrist and patient
Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
14:20-15:05
Conversation between psychiatrist and patient
Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
15:05–15:50
Implementing Psychedelic Therapies into the Healthcare System Today – Lessons of Five Years of Clinical Work with Ketamine and (Recently) Psilocybin in Germany
For many, psychedelic-assisted therapy in clinical settings still feels decades away. This talk outlines how the OVID Clinic Berlin is already making it a reality — as Europe's first psychedelic day clinic integrated into Germany's healthcare system.
Dr. med. Andrea Jungaberle
Chief Medical Officer (OVID Clinics Berlin); Co-founder and advisory board member (MIND Foundation)
15:05–15:50
Psühhiaatri ja patsiendi vestlus
For many, psychedelic-assisted therapy in clinical settings still feels decades away. This talk outlines how the OVID Clinic Berlin is already making it a reality — as Europe's first psychedelic day clinic integrated into Germany's healthcare system.
Dr. med. Andrea Jungaberle
Chief Medical Officer (OVID Clinics Berlin); Co-founder and advisory board member (MIND Foundation)
15:05–15:50
Implementing Psychedelic Therapies into the Healthcare System Today – Lessons of Five Years of Clinical Work with Ketamine and (Recently) Psilocybin in Germany
For many, psychedelic-assisted therapy in clinical settings still feels decades away. This talk outlines how the OVID Clinic Berlin is already making it a reality — as Europe's first psychedelic day clinic integrated into Germany's healthcare system.
Dr. med. Andrea Jungaberle
Chief Medical Officer (OVID Clinics Berlin); Co-founder and advisory board member (MIND Foundation)
16:20–17:05
Panel discussion
A Therapist’s Perspective on Psychedelic-Assisted Therapy Training
Kaire Valgeväli
Gestalt psychotherapist (Psychotherapist)
Ethel Rosenfeldt
Psychological counselor
Dr Triin Arbo
Child and Adolescent Psychiatry (Tasapisitasakaal)
Viktoria Saat
Psychologist, coach (Viktoria Saat Consulting)
16:20–17:05
Vestlusring
A Therapist’s Perspective on Psychedelic-Assisted Therapy Training
Kaire Valgeväli
Gestalt psychotherapist (Psychotherapist)
Ethel Rosenfeldt
Psychological counselor
Dr Triin Arbo
Child and Adolescent Psychiatry (Tasapisitasakaal)
Viktoria Saat
Psychologist, coach (Viktoria Saat Consulting)
16:20–17:05
Panel discussion
A Therapist’s Perspective on Psychedelic-Assisted Therapy Training
Kaire Valgeväli
Gestalt psychotherapist (Psychotherapist)
Ethel Rosenfeldt
Psychological counselor
Dr Triin Arbo
Child and Adolescent Psychiatry (Tasapisitasakaal)
Viktoria Saat
Psychologist, coach (Viktoria Saat Consulting)
17:05–17:15
·
Closing remarks
13:20–14:20
·
Closing remarks
17:05–17:15
·
Closing remarks
Synapse Lounge
Synapse Lounge
Networking event. More info TBA.
TAIP Foundation reserves the right to make changes to the program.
Standard tickets are now on sale. Prices valid until September 7.
Group Discount
For groups of 3 to 5 participants, the ticket price is €169 per person (valid until 7 September).
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee